|
1
|
Clapier CR and Cairns BR: The biology of
chromatin remodeling complexes. Annu Rev Biochem. 78:273–304. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Vogelstein B, Papadopoulos N, Velculescu
VE, Zhou S, Diaz LA Jr and Kinzler KW: Cancer genome landscapes.
Science. 339:1546–1558. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Saha A, Wittmeyer J and Cairns BR:
Chromatin remodelling: The industrial revolution of DNA around
histones. Nat Rev Mol Cell Biol. 7:437–447. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Lorch Y, Maier-Davis B and Kornberg RD:
Mechanism of chromatin remodeling. Proc Natl Acad Sci USA.
107:3458–3462. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Isakoff MS, Sansam CG, Tamayo P,
Subramanian A, Evans JA, Fillmore CM, Wang X, Biegel JA, Pomeroy
SL, Mesirov JP, et al: Inactivation of the Snf5 tumor suppressor
stimulates cell cycle progression and cooperates with p53 loss in
oncogenic transformation. Proc Natl Acad Sci USA. 102:17745–17750.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Medina PP, Carretero J, Ballestar E,
Angulo B, Lopez-Rios F, Esteller M and Sanchez-Cespedes M:
Transcriptional targets of the chromatin-remodelling factor
SMARCA4/BRG1 in lung cancer cells. Hum Mol Genet. 14:973–982. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Mohrmann L and Verrijzer CP: Composition
and functional specificity of SWI2/SNF2 class chromatin remodeling
complexes. Biochim Biophys Acta. 1681:59–73. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Wang W, Côté J, Xue Y, Zhou S, Khavari PA,
Biggar SR, Muchardt C, Kalpana GV, Goff SP, Yaniv M, et al:
Purification and biochemical heterogeneity of the mammalian SWI-SNF
complex. EMBO J. 15:5370–5382. 1996.PubMed/NCBI
|
|
9
|
Phelan ML, Sif S, Narlikar GJ and Kingston
RE: Reconstitution of a core chromatin remodeling complex from
SWI/SNF subunits. Mol Cell. 3:247–253. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kaeser MD, Aslanian A, Dong MQ, Yates JR
III and Emerson BM: BRD7, a novel PBAF-specific SWI/SNF subunit, is
required for target gene activation and repression in embryonic
stem cells. J Biol Chem. 283:32254–32263. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Wang X, Nagl NG Jr, Wilsker D, Van Scoy M,
Pacchione S, Yaciuk P, Dallas PB and Moran E: Two related ARID
family proteins are alternative subunits of human SWI/SNF
complexes. Biochem J. 383:319–325. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Chunder N, Mandal S, Basu D, Roy A,
Roychoudhury S and Panda CK: Deletion mapping of chromosome 1 in
early onset and late onset breast tumors - a comparative study in
eastern India. Pathol Res Pract. 199:313–321. 2003. View Article : Google Scholar
|
|
13
|
Varela I, Tarpey P, Raine K, Huang D, Ong
CK, Stephens P, Davies H, Jones D, Lin ML, Teague J, et al: Exome
sequencing identifies frequent mutation of the SWI/SNF complex gene
PBRM1 in renal carcinoma. Nature. 469:539–542. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Jones S, Li M, Parsons DW, Zhang X,
Wesseling J, Kristel P, Schmidt MK, Markowitz S, Yan H, Bigner D,
et al: Somatic mutations in the chromatin remodeling gene ARID1A
occur in several tumor types. Hum Mutat. 33:100–103. 2012.
View Article : Google Scholar
|
|
15
|
Zang ZJ, Cutcutache I, Poon SL, Zhang SL,
McPherson JR, Tao J, Rajasegaran V, Heng HL, Deng N, Gan A, et al:
Exome sequencing of gastric adenocarcinoma identifies recurrent
somatic mutations in cell adhesion and chromatin remodeling genes.
Nat Genet. 44:570–574. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Gui Y, Guo G, Huang Y, Hu X, Tang A, Gao
S, Wu R, Chen C, Li X, Zhou L, et al: Frequent mutations of
chromatin remodeling genes in transitional cell carcinoma of the
bladder. Nat Genet. 43:875–878. 2011. View
Article : Google Scholar : PubMed/NCBI
|
|
17
|
Agrawal N, Jiao Y, Bettegowda C, Hutfless
SM, Wang Y, David S, Cheng Y, Twaddell WS, Latt NL, Shin EJ, et al:
Comparative genomic analysis of esophageal adenocarcinoma and
squamous cell carcinoma. Cancer Discov. 2:899–905. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Streppel MM, Lata S, DelaBastide M,
Montgomery EA, Wang JS, Canto MI, Macgregor-Das AM, Pai S, Morsink
FH, Offerhaus GJ, et al: Next-generation sequencing of endoscopic
biopsies identifies ARID1A as a tumor-suppressor gene in Barrett's
esophagus. Oncogene. 33:347–357. 2014. View Article : Google Scholar
|
|
19
|
Huang J, Deng Q, Wang Q, Li KY, Dai JH, Li
N, Zhu ZD, Zhou B, Liu XY, Liu RF, et al: Exome sequencing of
hepatitis B virus-associated hepatocellular carcinoma. Nat Genet.
44:1117–1121. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Fujimoto A, Totoki Y, Abe T, Boroevich KA,
Hosoda F, Nguyen HH, Aoki M, Hosono N, Kubo M, Miya F, et al:
Whole-genome sequencing of liver cancers identifies etiological
influences on mutation patterns and recurrent mutations in
chromatin regulators. Nat Genet. 44:760–764. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Dulak AM, Stojanov P, Peng S, Lawrence MS,
Fox C, Stewart C, Bandla S, Imamura Y, Schumacher SE, Shefler E, et
al: Exome and whole-genome sequencing of esophageal adenocarcinoma
identifies recurrent driver events and mutational complexity. Nat
Genet. 45:478–486. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Imielinski M, Berger AH, Hammerman PS,
Hernandez B, Pugh TJ, Hodis E, Cho J, Suh J, Capelletti M,
Sivachenko A, et al: Mapping the hallmarks of lung adenocarcinoma
with massively parallel sequencing. Cell. 150:1107–1120. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Shain AH, Giacomini CP, Matsukuma K,
Karikari CA, Bashyam MD, Hidalgo M, Maitra A and Pollack JR:
Convergent structural alterations define SWItch/Sucrose
NonFermentable (SWI/SNF) chromatin remodeler as a central tumor
suppressive complex in pancreatic cancer. Proc Natl Acad Sci USA.
109:E252–E259. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Biankin AV, Waddell N, Kassahn KS, Gingras
MC, Muthuswamy LB, Johns AL, Miller DK, Wilson PJ, Patch AM, Wu J,
et al: Australian Pancreatic Cancer Genome Initiative: Pancreatic
cancer genomes reveal aberrations in axon guidance pathway genes.
Nature. 491:399–405. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Cornen S, Adelaide J, Bertucci F, Finetti
P, Guille A, Birnbaum DJ, Birnbaum D and Chaffanet M: Mutations and
deletions of ARID1A in breast tumors. Oncogene. 31:4255–4256. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Stephens PJ, Tarpey PS, Davies H, Van Loo
P, Greenman C, Wedge DC, Nik-Zainal S, Martin S, Varela I, Bignell
GR, et al: Oslo Breast Cancer Consortium (OSBREAC): The landscape
of cancer genes and mutational processes in breast cancer. Nature.
486:400–404. 2012.PubMed/NCBI
|
|
27
|
Giulino-Roth L, Wang K, MacDonald TY,
Mathew S, Tam Y, Cronin MT, Palmer G, Lucena-Silva N, Pedrosa F,
Pedrosa M, et al: Targeted genomic sequencing of pediatric Burkitt
lymphoma identifies recurrent alterations in antiapoptotic and
chromatin-remodeling genes. Blood. 120:5181–5184. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Love C, Sun Z, Jima D, Li G, Zhang J,
Miles R, Richards KL, Dunphy CH, Choi WW, Srivastava G, et al: The
genetic landscape of mutations in Burkitt lymphoma. Nat Genet.
44:1321–1325. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Sausen M, Leary RJ, Jones S, Wu J,
Reynolds CP, Liu X, Blackford A, Parmigiani G, Diaz LA Jr,
Papadopoulos N, et al: Integrated genomic analyses identify ARID1A
and ARID1B alterations in the childhood cancer neuroblastoma. Nat
Genet. 45:12–17. 2013. View Article : Google Scholar :
|
|
30
|
Jones S, Wang TL, Shih IeM, Mao TL,
Nakayama K, Roden R, Glas R, Slamon D, Diaz LA Jr, Vogelstein B, et
al: Frequent mutations of chromatin remodeling gene ARID1A in
ovarian clear cell carcinoma. Science. 330:228–231. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Wiegand KC, Shah SP, Al-Agha OM, Zhao Y,
Tse K, Zeng T, Senz J, McConechy MK, Anglesio MS, Kalloger SE, et
al: ARID1A mutations in endometriosis-associated ovarian
carcinomas. N Engl J Med. 363:1532–1543. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Guan B, Mao TL, Panuganti PK, Kuhn E,
Kurman RJ, Maeda D, Chen E, Jeng YM, Wang TL and Shih IeM: Mutation
and loss of expression of ARID1A in uterine low-grade endometrioid
carcinoma. Am J Surg Pathol. 35:625–632. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Guan B, Gao M, Wu C-H, Wang T-L and Shih
IeM: Functional analysis of in-frame indel ARID1A mutations reveals
new regulatory mechanisms of its tumor suppressor functions.
Neoplasia. 14:986–993. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Luchini C, Veronese N, Solmi M, Cho H, Kim
J-H, Chou A, Gill AJ, Faraj SF, Chaux A, Netto GJ, et al:
Prognostic role and implications of mutation status of tumor
suppressor gene ARID1A in cancer: A systematic review and
meta-analysis. Oncotarget. Sept 8–2015.Epub ahead of print.
PubMed/NCBI
|
|
35
|
Guan B, Wang TL and Shih IeM: ARID1A, a
factor that promotes formation of SWI/SNF-mediated chromatin
remodeling, is a tumor suppressor in gynecologic cancers. Cancer
Res. 71:6718–6727. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Yamamoto S, Tsuda H, Takano M, Tamai S and
Matsubara O: Loss of ARID1A protein expression occurs as an early
event in ovarian clear-cell carcinoma development and frequently
coexists with PIK3CA mutations. Mod Pathol. 25:615–624. 2012.
View Article : Google Scholar
|
|
37
|
Veras E, Mao TL, Ayhan A, Ueda S, Lai H,
Hayran M, Shih IeM and Kurman RJ: Cystic and adenofibromatous clear
cell carcinomas of the ovary: distinctive tumors that differ in
their pathogenesis and behavior: a clinicopathologic analysis of
122 cases. Am J Surg Pathol. 33:844–853. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Wu CH, Mao TL, Vang R, Ayhan A, Wang TL,
Kurman RJ and Shih IeM: Endocervical-type mucinous borderline
tumors are related to endometrioid tumors based on mutation and
loss of expression of ARID1A. Int J Gynecol Pathol. 31:297–303.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Ayhan A, Mao TL, Seckin T, Wu CH, Guan B,
Ogawa H, Futagami M, Mizukami H, Yokoyama Y, Kurman RJ, et al: Loss
of ARID1A expression is an early molecular event in tumor
progression from ovarian endometriotic cyst to clear cell and
endometrioid carcinoma. Int J Gynecol Cancer. 22:1310–1315. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Vercellini P, Crosignani P, Somigliana E,
Viganò P, Buggio L, Bolis G and Fedele L: The 'incessant
menstruation' hypothesis: A mechanistic ovarian cancer model with
implications for prevention. Hum Reprod. 26:2262–2273. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Yamaguchi K, Mandai M, Toyokuni S,
Hamanishi J, Higuchi T, Takakura K and Fujii S: Contents of
endometriotic cysts, especially the high concentration of free
iron, are a possible cause of carcinogenesis in the cysts through
the iron-induced persistent oxidative stress. Clin Cancer Res.
14:32–40. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Guan B, Rahmanto YS, Wu R-C, Wang Y, Wang
Z, Wang T-L and Shih IeM: Roles of deletion of Arid1a, a tumor
suppressor, in mouse ovarian tumorigenesis. J Natl Cancer Inst.
106:dju1462014. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Tanwar PS, Kaneko-Tarui T, Lee HJ, Zhang L
and Teixeira JM: PTEN loss and HOXA10 expression are associated
with ovarian endometrioid adenocarcinoma differentiation and
progression. Carcinogenesis. 34:893–901. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Kuo KT, Mao TL, Jones S, Veras E, Ayhan A,
Wang TL, Glas R, Slamon D, Velculescu VE, Kuman RJ, et al: Frequent
activating mutations of PIK3CA in ovarian clear cell carcinoma. Am
J Pathol. 174:1597–1601. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Yamamoto S, Tsuda H, Takano M, Iwaya K,
Tamai S and Matsubara O: PIK3CA mutation is an early event in the
development of endometriosis-associated ovarian clear cell
adenocarcinoma. J Pathol. 225:189–194. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Yamamoto S, Tsuda H, Takano M, Tamai S and
Matsubara O: PIK3CA mutations and loss of ARID1A protein expression
are early events in the development of cystic ovarian clear cell
adenocarcinoma. Virchows Arch. 460:77–87. 2012. View Article : Google Scholar
|
|
47
|
Cheung LW, Hennessy BT, Li J, Yu S, Myers
AP, Djordjevic B, Lu Y, Stemke-Hale K, Dyer MD, Zhang F, et al:
High frequency of PIK3R1 and PIK3R2 mutations in endometrial cancer
elucidates a novel mechanism for regulation of PTEN protein
stability. Cancer Discov. 1:170–185. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Llobet D, Pallares J, Yeramian A,
Santacana M, Eritja N, Velasco A, Dolcet X and Matias-Guiu X:
Molecular pathology of endometrial carcinoma: Practical aspects
from the diagnostic and therapeutic viewpoints. J Clin Pathol.
62:777–785. 2009. View Article : Google Scholar
|
|
49
|
Wiegand KC, Lee AF, Al-Agha OM, Chow C,
Kalloger SE, Scott DW, Steidl C, Wiseman SM, Gascoyne RD, Gilks B,
et al: Loss of BAF250a (ARID1A) is frequent in high-grade
endometrial carcinomas. J Pathol. 224:328–333. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
McConechy MK, Ding J, Cheang MC, Wiegand
KC, Senz J, Tone AA, Yang W, Prentice LM, Tse K, Zeng T, et al: Use
of mutation profiles to refine the classification of endometrial
carcinomas. J Pathol. 228:20–30. 2012.PubMed/NCBI
|
|
51
|
Liang H, Cheung LW, Li J, Ju Z, Yu S,
Stemke-Hale K, Dogruluk T, Lu Y, Liu X, Gu C, et al: Whole-exome
sequencing combined with functional genomics reveals novel
candidate driver cancer genes in endometrial cancer. Genome Res.
22:2120–2129. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Bosse T, ter Haar NT, Seeber LM, v Diest
PJ, Hes FJ, Vasen HF, Nout RA, Creutzberg CL, Morreau H and Smit
VT: Loss of ARID1A expression and its relationship with PI3K-Akt
pathway alterations, TP53 and microsatellite instability in
endometrial cancer. Mod Pathol. 26:1525–1535. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Mao TL, Ardighieri L, Ayhan A, Kuo KT, Wu
CH, Wang TL and Shih IeM: Loss of ARID1A expression correlates with
stages of tumor progression in uterine endometrioid carcinoma. Am J
Surg Pathol. 37:1342–1348. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Hoang LN, McConechy MK, Meng B, McIntyre
JB, Ewanowich C, Gilks CB, Huntsman DG, Köbel M and Lee CH:
Targeted mutation analysis of endometrial clear cell carcinoma.
Histopathology. 66:664–674. 2015. View Article : Google Scholar
|
|
55
|
Fadare O, Renshaw IL and Liang SX: Does
the loss of ARID1A (BAF-250a) expression in endometrial clear cell
carcinomas have any clinicopathologic significance? A pilot
assessment. J Cancer. 3:129–136. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Zhang ZM, Xiao S, Sun GY, Liu YP, Zhang
FH, Yang HF, Li J, Qiu HB, Liu Y, Zhang C, et al: The
clinicopathologic significance of the loss of BAF250a (ARID1A)
expression in endometrial carcinoma. Int J Gynecol Cancer.
24:534–540. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Fadare O, Gwin K, Desouki MM, Crispens MA,
Jones HW III, Khabele D, Liang SX, Zheng W, Mohammed K, Hecht JL,
et al: The clinicopathologic significance of p53 and BAF-250a
(ARID1A) expression in clear cell carcinoma of the endometrium. Mod
Pathol. 26:1101–1110. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
van Nagell JR Jr and Hoff JT: Transvaginal
ultrasonography in ovarian cancer screening: Current perspectives.
Int J Womens Health. 6:25–33. 2013. View Article : Google Scholar :
|
|
59
|
Takano M, Kikuchi Y, Kudoh K, Goto T,
Furuya K, Kikuchi R, Kita T, Fujiwara K, Shiozawa T and Aoki D:
Weekly administration of temsirolimus for heavily pretreated
patients with clear cell carcinoma of the ovary: A report of six
cases. Int J Clin Oncol. 16:605–609. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Scott JD and Williams RM: Chemistry and
biology of the tetrahydroisoquinoline antitumor antibiotics. Chem
Rev. 102:1669–1730. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Kwan JC and Luesch H: Weapons in disguise
- activating mechanisms and protecting group chemistry in nature.
Chemistry. 16:13020–13029. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Rahman M, Nakayama K, Ishibashi T,
Ishikawa M, Rahman MT, Katagiri H, Katagiri A, Iida K, Kikuchi Y
and Miyazaki K: A case of stage III c ovarian clear cell carcinoma:
The role for predictive biomarkers and targeted therapies. Int J
Mol Sci. 14:6067–6073. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Bitler BG, Aird KM, Garipov A, Li H,
Amatangelo M, Kossenkov AV, Schultz DC, Liu Q, Shih IeM,
Conejo-Garcia JR, et al: Synthetic lethality by targeting EZH2
methyltransferase activity in ARID1A-mutated cancers. Nat Med.
1:231–238. 2015.
|
|
64
|
Helming KC, Wang X, Wilson BG, Vazquez F,
Haswell JR, Manchester HE, Kim Y, Kryukov GV, Ghandi M, Aguirre AJ,
et al: ARID1B is a specific vulnerability in ARID1A-mutant cancers.
Nat Med. 20:251–254. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Park JH, Lee C, Suh JH, Chae JY, Kim HW
and Moon KC: Decreased ARID1A expression correlates with poor
prognosis of clear cell renal cell carcinoma. Hum Pathol.
46:454–460. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Wei XL, Wang DS, Xi SY, Wu WJ, Chen DL,
Zeng ZL, Wang RY, Huang YX, Jin Y, Wang F, et al: Clinicopathologic
and prognostic relevance of ARID1A protein loss in colorectal
cancer. World J Gastroenterol. 20:18404–18412. 2014. View Article : Google Scholar
|
|
67
|
Faraj SF, Chaux A, Gonzalez-Roibon N,
Munari E, Ellis C, Driscoll T, Schoenberg MP, Bivalacqua TJ, Shih
IeM and Netto GJ: ARID1A immunohistochemistry improves outcome
prediction in invasive urothelial carcinoma of urinary bladder. Hum
Pathol. 45:2233–2239. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Wiegand KC, Sy K, Kalloger SE, Li-Chang H,
Woods R, Kumar A, Streutker CJ, Hafezi-Bakhtiari S, Zhou C, Lim HJ,
et al: ARID1A/BAF250a as a prognostic marker for gastric carcinoma:
A study of 2 cohorts. Hum Pathol. 45:1258–1268. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Yokoyama Y, Matsushita Y, Shigeto T,
Futagami M and Mizunuma H: Decreased ARID1A expression is
correlated with chemoresistance in epithelial ovarian cancer. J
Gynecol Oncol. 25:58–63. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Itamochi H, Oumi N, Oishi T, Shoji T,
Fujiwara H, Sugiyama T, Suzuki M, Kigawa J and Harada T: Loss of
ARID1A expression is associated with poor prognosis in patients
with stage I/II clear cell carcinoma of the ovary. Int J Clin
Oncol. 20:967–973. 2015. View Article : Google Scholar : PubMed/NCBI
|
